Interview with Ralf Dahmen, Managing Director, Galderma
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
Address: Level 3, 235 Pyrmont Street,Pyrmont, NSW 2009
Sydney, Australia
Tel: +61 (0)2 8569 1400
Web: http://www.novotech-cro.com/
Established in 1996, Novotech is the largest independent CRO in Australia. With operations in Australia, New Zealand, the United States, India, and South Korea, Novotech’s service offering has come to be recognized for its quality both by our clients, as well as industry analyst groups. The demand for global clinical outsourcing services continues to grow at a rapid pace, with Asia providing the new frontier. Headquartered in Australia, Novotech is the ideal gateway for expansion of clinical programs into the region.
Novotech’s comprehensive range of services extend the full spectrum of clinical drug development needs. Novotech’s Australian Head Office is situated in Sydney, with regional offices in Melbourne and Brisbane providing easy access to the most important population centres in Australia. Supported by regional staff across the country and in New Zealand, Novotech’s coverage of the Australia/New Zealand region is second to none.
Novotech Sydney is ISO 9001 certified and is regularly audited not only by clients, but external quality endorsement organisations as part of maintaining ISO credentials.
Audits, Medical Writing, Clinical Trials, Biostatistics, Generics, Regulatory Affairs
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
See our Cookie Privacy Policy Here
